STOCK TITAN

DAXOR CORP - DXR STOCK NEWS

Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.

Daxor Corp (DXR) delivers critical advancements in blood volume measurement through its FDA-cleared BVA-100 technology. This page provides investors and healthcare professionals with centralized access to official news, financial updates, and clinical developments related to DXR’s diagnostic innovations.

Track press releases covering product milestones, peer-reviewed research validations, and strategic partnerships. Stay informed about quarterly earnings, regulatory filings, and advancements in fluid management diagnostics. All content is sourced directly from verified company communications to ensure accuracy.

Key updates include BVA-100 adoption metrics, clinical trial outcomes, and operational expansions. Bookmark this page for real-time insights into DXR’s role in transforming patient diagnostics through precise blood volume analysis. Regularly updated to serve as your primary resource for unbiased, factual Daxor Corp developments.

Rhea-AI Summary

Daxor Corporation (NYSE: DXR) recently announced the publication of new data in Critical Care, highlighting the effectiveness of its BVA-100 diagnostic blood test in assessing blood volume alterations in critically ill COVID-19 patients. The research reveals significant capillary damage and blood volume deficits in these patients, emphasizing the need for fluid management. Following this, a multi-center study is underway at prominent hospitals including Wake Forest and NYU Langone Health to further explore these findings, potentially enhancing clinical outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
covid-19
-
Rhea-AI Summary

Daxor Corporation (NYSE: DXR) has announced a distribution agreement with Concordance Healthcare Solutions, enhancing the availability of its BVA-100® diagnostic blood test across U.S. healthcare facilities. This partnership aims to promote blood volume measurement for improved patient outcomes in conditions like heart failure. Daxor's CEO, Michael Feldschuh, emphasized that this collaboration will boost sales and awareness of their technology. Concordance's Senior Director highlighted that the BVA-100 will help reduce readmissions and healthcare costs, positively impacting patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
-
Rhea-AI Summary

Daxor Corporation (NYSE: DXR) announced an expert analysis titled, "Anemia and Heart Failure: Guidance for Clinicians and Trialists," published in the American College of Cardiology. This analysis highlights the significance of measuring total blood volume in managing anemia among heart failure patients, a condition affecting over 6 million Americans. Daxor's BVA-100 Blood Volume Analyzer is emphasized as a critical tool for accurate blood volume assessment, informing treatment strategies. The company is also developing new testing platforms supported by the U.S. Department of Defense and NIH, expected in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none
Rhea-AI Summary

Daxor Corporation (NYSE: DXR), a leader in blood volume measurement technology, announces that CEO Michael Feldschuh will present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021, at 4:30 PM ET. He will discuss Daxor's business model, growth strategy, and next-generation technology. The event will be virtual, allowing investors to register for attendance or request one-on-one meetings. The presentation will be available for live streaming and replay on Daxor's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
conferences
-
Rhea-AI Summary

Daxor Corporation (NYSE: DXR) reported a significant 61% increase in Q1 2021 revenue year-over-year, attributed to the easing of COVID restrictions. The company opened five new customer accounts utilizing its BVA-100 Blood Volume Analyzer and anticipates more acquisitions in Q3 2021, expanding its presence in major medical centers. Daxor is enhancing its sales team to support growth, with expectations to access over 70% of client hospitals by the end of Q2 2021. The company is also advancing next-generation diagnostic technologies that aim to improve patient outcomes and operational efficiency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
-
Rhea-AI Summary

Daxor Corporation (NYSE: DXR) announces the start of a multi-center clinical trial with Veterans Affairs Medical Centers to assess Blood Volume Analysis (BVA) for managing acute decompensated heart failure (ADHF) using the BVA-100 blood test. The NIH intends to fund this landmark study, which aims to enhance treatment outcomes for over 6 million heart failure patients in the U.S. Previous data indicates that BVA-100 guided care could reduce patient mortality by over 82% and readmissions by 56%. The study is vital for validating Daxor's clinical guidance system and advancing heart failure management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
Rhea-AI Summary

Daxor Corporation (NYSE: DXR) announced new findings regarding the BVA-100 blood test's effectiveness in managing Postural Tachycardia Syndrome (POTS). Published in the Journal of the American College of Cardiology, the study demonstrated that a high sodium diet increased plasma volume and reduced heart rate in POTS patients. The BVA-100 test provides accurate blood volume measurements, affirming its role as a crucial tool for treatment optimization in POTS. Daxor continues to position itself as a leader in blood volume measurement technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
none
-
Rhea-AI Summary

Daxor Corporation (NYSE: DXR) announces that President and CEO Michael Feldschuh will participate in the Benzinga Biotech Small Cap Conference on March 24-25, 2021. His presentation on March 24 at 12:30 PM EDT will cover the company's business model, growth strategy, and advancements in blood volume measurement technology, including updates on research and contracts with the US Department of Defense. Investors can register to view the presentation and request one-on-one meetings with Feldschuh.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Daxor Corporation (NYSE: DXR) announced that President and CEO Michael Feldschuh will present at the 2021 Emerging Growth Virtual Conference on March 17-19, 2021. He will discuss Daxor's recent achievements, including revenue growth, research advancements, and new contracts with the US Department of Defense. The company's BVA-100® blood test aims to improve management in critical care, COVID-19, and heart failure. Investors can view the presentation online and request one-on-one meetings with Feldschuh afterward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
conferences
Rhea-AI Summary

Daxor Corporation (NYSE: DXR) has secured a $750,000 phase-two contract from the USAF to enhance its blood volume measurement technology. This contract marks the fourth award from the DoD in two years, totaling over $2 million. The funding will facilitate the development of a new fluorescent tracer and optical sensing technology, expanding the capabilities of the BVA-100 Blood Volume Analyzer for both military and civilian applications. The innovative system aims to improve patient resuscitation and treatment outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.53%
Tags
none
DAXOR CORP

NYSE:DXR

DXR Rankings

DXR Stock Data

37.61M
2.12M
57%
2.13%
0.23%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
NEW YORK